<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24575748</article-id>
      <article-id pub-id-type="pmc">3943276</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-12-47</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-47</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Yanagawa</surname>
            <given-names>Senichiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>qqry3v7d@silk.ocn.ne.jp</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A2">
          <name>
            <surname>Tanabe</surname>
            <given-names>Kazuaki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ktanabe2@hiroshima-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Suzuki</surname>
            <given-names>Takahisa</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>takahsuzuki@yahoo.co.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Tokumoto</surname>
            <given-names>Noriaki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gnoritoku0424@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Arihiro</surname>
            <given-names>Koji</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>arihiro@hiroshima-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Ohdan</surname>
            <given-names>Hideki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hohdan@hiroshima-u.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hirohima 734-8551, Japan</aff>
      <aff id="I2"><label>2</label>Department of Anatomical Pathology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hirohima 734-8551, Japan</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>2</month>
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <fpage>47</fpage>
      <lpage>47</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Yanagawa et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Yanagawa et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.wjso.com/content/12/1/47"/>
      <abstract>
        <p>A 49-year-old man was admitted to our hospital with a 1-month history of dysphagia. An upper endoscopy revealed a lower esophageal submucosal tumor. Immunohistochemical staining of the biopsy specimen revealed KIT positivity. Thus, the tumor was diagnosed as a gastrointestinal stromal tumor (GIST). After 6&#xA0;months of imatinib treatment, the tumor decreased from 92&#xA0;mm&#x2009;&#xD7;&#x2009;55&#xA0;mm&#x2009;&#xD7;&#x2009;80&#xA0;mm to 65&#xA0;mm&#x2009;&#xD7;&#x2009;35&#xA0;mm&#x2009;&#xD7;&#x2009;55&#xA0;mm in diameter, and surgery was performed. The tumor was completely resected without rupture, by partial esophagogastric resection through a thoracotomy incision, using an abdominal laparoscopic approach. Immunohistochemical staining revealed that the tumor was negative for c-kit but positive for CD34. Genetic examination showed that the tumor had a mutation in exon 11. The patient experienced minor leakage but recovered conservatively. Adjuvant imatinib was initiated 64&#xA0;days after surgery. We report this rare case to show the potential of preoperative imatinib treatment in patients with large esophageal GISTs, to achieve complete resection without rupture.</p>
      </abstract>
      <kwd-group>
        <kwd>Esophageal GIST</kwd>
        <kwd>Neoadjuvant chemotherapy</kwd>
        <kwd>Imatinib</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract, commonly found in the stomach (60% to 70%) and small intestine (20% to 30%) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Surgery is the first treatment for resectable GISTs, which cures approximately 60% of patients [<xref ref-type="bibr" rid="B3">3</xref>]. However, the prognosis of patients who relapse is poor. Imatinib mesylate is now the standard drug for patients with unresectable or metastatic GISTs and was recently approved for use as an adjuvant treatment [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Currently, there is no evidence of an effective neoadjuvant therapy for GISTs, especially for very large primary GISTs, which have an increased risk of a positive resection margin [<xref ref-type="bibr" rid="B6">6</xref>]. As esophageal GISTs are very rare, accounting for &lt;2% of all GISTs [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B7">7</xref>], the available literature is limited. Moreover, the use of imatinib therapy followed by surgery has been published only for a few cases [<xref ref-type="bibr" rid="B8">8</xref>]. We report a large esophageal GIST in a 49-year-old man who underwent surgery after neoadjuvant chemotherapy.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 49-year-old man was admitted to our hospital with a 1-month history of dysphagia. He did not have any history of illness or any significant family history. Physical examination revealed no abnormalities. Standard laboratory test results on serum and urine showed no significant findings. Tumor markers such as carcinoembryonic antigen, carbohydrate antigenic determinant 19-9 and squamous cell carcinoma antigen were also within the reference limits. An upper endoscopy revealed a submucosal tumor with a narrowed lumen in the lower esophagus (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>A). After a fine-needle aspiration biopsy, the tumor was diagnosed as a GIST, characterized pathologically by H &amp; E staining and immunostaining (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>B,C,D). A computed tomography (CT) scan showed a mass, 92&#xA0;mm&#x2009;&#xD7;&#x2009;55&#xA0;mm&#x2009;&#xD7;&#x2009;80&#xA0;mm in diameter (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>A), at the lower esophagus and the maximum standardized uptake value (SUV max) was 4.9 on a positron emission tomography (PET)-CT scan (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>B). There was no apparent distant metastasis. The tumor was classified as intermediate risk according to Fletcher&#x2019;s classification [<xref ref-type="bibr" rid="B9">9</xref>]. It was judged to be resectable, but with a risk for rupture during resection because of the size and localization of the lesion. Therefore the patient received neoadjuvant imatinib (400&#xA0;mg/day) treatment and was followed-up for 2&#xA0;months with CT scans to assess the therapeutic effect. He was treated for 6&#xA0;months with chemotherapy and the tumor shrank by 25% (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>C). A PET-CT scan showed a reduction in SUV max to 1.2 (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>D).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Preoperative image and tumor biopsy images. (A)</bold> Endoscopic image taken before chemotherapy showing the tumor with a smooth surface in the lower esophagus. Histopathologically, H &amp; E staining showed that the spindle tumor cells had no mitotic activity, as shown at&#x2009;&#xD7;&#x2009;200 <bold>(B)</bold>. The tumor cells were positive for c-kit, as shown at&#x2009;&#xD7;&#x2009;200, <bold>(C)</bold> and CD34, as shown at&#x2009;&#xD7;&#x2009;200, <bold>(D)</bold> using immunohistochemistry.</p>
        </caption>
        <graphic xlink:href="1477-7819-12-47-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>CT and PET-CT images. (A)</bold> CT scan before chemotherapy. The tumor was 92&#x2009;&#xD7;&#x2009;55&#xA0;mm&#x2009;&#xD7;&#x2009;80&#xA0;mm in diameter. <bold>(B)</bold> PET-CT scan before chemotherapy. SUV max was 4.9. <bold>(C)</bold> CT scan after chemotherapy. The tumor was 70&#xA0;mm&#x2009;&#xD7;&#x2009;37&#xA0;mm&#x2009;&#xD7;&#x2009;60&#xA0;mm in diameter. <bold>(D)</bold> PET-CT scan after chemotherapy. SUV max was 1.2.</p>
        </caption>
        <graphic xlink:href="1477-7819-12-47-2"/>
      </fig>
      <p>The patient underwent surgery after the chemotherapy. The surgical procedure was a partial esophagogastric resection through a thoracotomy incision, using an abdominal laparoscopic approach. A lymphadenectomy was not performed. On gross examination, the resected tumor was soft and had shrunk to 65&#xA0;mm&#x2009;&#xD7;&#x2009;35&#xA0;mm&#x2009;&#xD7;&#x2009;45&#xA0;mm in diameter (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>A). The esophageal mucosa appeared normal without ulcerations. Histological analysis showed that the tumor consisted of spindle cells with no mitotic activity (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>B). Immunohistochemical staining revealed that the spindle cells were negative for c-kit (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>C) but positive for CD34 (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>D). Genetic examination showed that the tumor had an exon 11 mutation.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Resected surgical specimen. (A)</bold> The resected tumor was approximately 65&#xA0;mm&#x2009;&#xD7;&#x2009;35&#x2009;&#xD7;&#x2009;55&#xA0;mm in diameter. <bold>(B)</bold> Histopathologically, H &amp; E staining showed that the tumor cells had no necrosis and mitotic activity, as shown at&#x2009;&#xD7;&#x2009;200. The tumor cells were negative for c-kit, as shown at&#x2009;&#xD7;&#x2009;200, <bold>(C)</bold> and positive for CD34, as shown at&#x2009;&#xD7;&#x2009;200, <bold>(D)</bold> using immunohistochemistry.</p>
        </caption>
        <graphic xlink:href="1477-7819-12-47-3"/>
      </fig>
      <p>The patient experienced aspiration pneumonia and minor leakage after the operation, but recovered conservatively from both conditions. He was discharged 52&#xA0;days after the surgery, and adjuvant chemotherapy (imatinib, 400&#xA0;mg/day) was initiated at 64&#xA0;days after the surgery. There has been no recurrence for 12&#xA0;months post-surgery.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Complete surgical resection is the standard treatment for localized GISTs; however, 40% to 90% of curative resection patients experience recurrence [<xref ref-type="bibr" rid="B10">10</xref>]. Esophageal GISTs are rare, highly vascularized tumors. Large tumors specifically have a tendency to rupture or have a risk of a positive margin despite a macroscopically complete resection. Tumor rupture or the presence of a residual tumor is strongly associated with recurrence and poor prognosis [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p>
      <p>The biological potential of stomach or small intestinal GISTs is related to their size and mitotic activity, which may also be true of esophageal GISTs. The prognosis is commonly stratified according to the Joensuu risk criteria [<xref ref-type="bibr" rid="B3">3</xref>] and accurate risk stratification is important in considering adjuvant imatinib therapy. It has been established that 3&#xA0;years of adjuvant imatinib is beneficial for recurrence-free survival and overall survival for-high risk GISTs [<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>Although the benefit of imatinib for malignant or high-risk GISTs is beyond doubt, the clinical outcome of neoadjuvant treatment has not yet been established. In our case, we were able to a perform complete resection of the GIST owing to the decreased tumor size after the treatment with imatinib. The tumor was diagnosed to be of intermediate risk according to Fletcher&#x2019;s classification [<xref ref-type="bibr" rid="B9">9</xref>]. We used neoadjuvant imatinib (400&#xA0;mg/day for 6&#xA0;months) to achieve complete resection without rupture. In our case, there was no rupture during the operation and a pathologically negative margin was obtained. The appropriate duration of neoadjuvant therapy with imatinib is controversial. Most of the positive responses to chemotherapy occur within 6&#xA0;months of administration and secondary mutations may occur after 10&#xA0;months of treatment, hence some reports suggest 6&#xA0;months of neoadjuvant chemotherapy for GISTs [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. In our case, sufficient shrinkage of the tumor was attained after 6&#xA0;months of treatment; therefore, a minimal resection could be performed during esophagectomy. The reason for the negative c-kit and positive CD34 findings, despite the tumor being positive for both markers preoperatively, is unclear. These biomarker changes may be because of the therapeutic effect of imatinib; however, whether these findings are indicative of a pathological complete response is uncertain. Tumors could show a completely altered morphology and immunophenotype after imatinib treatment; thus, pathologists should be aware of this phenomenon [<xref ref-type="bibr" rid="B15">15</xref>]. There have been several case reports demonstrating that a complete response was obtained with imatinib treatment even in patients with metastatic GISTs [<xref ref-type="bibr" rid="B16">16</xref>].</p>
      <p>In summary, we reported a case of a large esophageal GIST that was successfully resected after imatinib treatment. Although the effects of neoadjuvant imatinib therapy on overall survival are not yet clear, long-term imatinib administration has the potential to promote curative surgery for some patients with large GISTs.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>We treated a case of a large esophageal GIST that was successfully resected after neoadjuvant imatinib treatment. When an esophageal GIST is a certain size, located in the narrow mediastinal space and is difficult to dissect, neoadjuvant imatinib treatment might be one of the options for a minimally invasive surgical resection without rupture.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CT: computed tomography; GIST: gastrointestinal stromal tumor; H &amp; E: hematoxylin and eosin; OS: overall survival; PET: positron emission tomography; SUV max: maximum standardized uptake value.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>SY and KT wrote the manuscript. SY, KT, TS and NT performed surgery. KA carried out the pathological examination. HO was involved in the final editing. All authors approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>No financial support was required.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Miettinen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sarlomo-Rikala</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lasota</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Gastrointestinal stromal tumours</article-title>
          <source>Ann Chir Gynaecol</source>
          <year>1998</year>
          <volume>87</volume>
          <fpage>278</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">9891765</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Miettinen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lasota</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2006</year>
          <volume>130</volume>
          <fpage>1466</fpage>
          <lpage>1478</lpage>
          <pub-id pub-id-type="pmid">17090188</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Joensuu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Vehtari</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Riihimaki</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nishida</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Steigen</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Brabec</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Plank</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Nilsson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Cirilli</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bordoni</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Magnusson</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Linke</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Sufliarsky</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Federico</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Jonasson</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Dei Tos</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Rutkowski</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts</article-title>
          <source>Lancet Oncol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>265</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70299-6</pub-id>
          <pub-id pub-id-type="pmid">22153892</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Eisenberg</surname>
            <given-names>BL</given-names>
          </name>
          <article-title>The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors</article-title>
          <source>Am J Clin Oncol</source>
          <year>2013</year>
          <volume>36</volume>
          <fpage>89</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1097/COC.0b013e31827a7f55</pub-id>
          <pub-id pub-id-type="pmid">23334483</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Dematteo</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Ballman</surname>
            <given-names>KV</given-names>
          </name>
          <name>
            <surname>Antonescu</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Maki</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Pisters</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Demetri</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Blackstein</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Blanke</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Von Mehren</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Brennan</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McCarter</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Polikoff</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>BR</given-names>
          </name>
          <name>
            <surname>Owzar</surname>
            <given-names>K</given-names>
          </name>
          <collab>American College of Surgeons Oncology Group (ACOSOG) intergroup Adjuvant GIST Study Team</collab>
          <article-title>Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>373</volume>
          <fpage>1097</fpage>
          <lpage>1104</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60500-6</pub-id>
          <pub-id pub-id-type="pmid">19303137</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Raut</surname>
            <given-names>CP</given-names>
          </name>
          <name>
            <surname>Posner</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Morgan</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zahrieh</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fletcher</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Demetri</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Bertagnolli</surname>
            <given-names>MM</given-names>
          </name>
          <article-title>Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>2325</fpage>
          <lpage>2331</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.05.3439</pub-id>
          <pub-id pub-id-type="pmid">16710031</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>HJ</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>SI</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DK</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YH</given-names>
          </name>
          <article-title>Surgical resection of esophageal gastrointestinal stromal tumors</article-title>
          <source>Ann Thorac Surg</source>
          <year>2009</year>
          <volume>87</volume>
          <fpage>1569</fpage>
          <lpage>1571</lpage>
          <pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.01.051</pub-id>
          <pub-id pub-id-type="pmid">19379907</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Blum</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Bilimoria</surname>
            <given-names>KY</given-names>
          </name>
          <name>
            <surname>Wayne</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>de Hoyos</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Talamonti</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Adley</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors</article-title>
          <source>Ann Thorac Surg</source>
          <year>2007</year>
          <volume>84</volume>
          <fpage>1717</fpage>
          <lpage>1723</lpage>
          <pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.05.071</pub-id>
          <pub-id pub-id-type="pmid">17954092</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fletcher</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Corless</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gorstein</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lasota</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Longley</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Miettinen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>O&#x2019;Leary</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Remotti</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Rubin</surname>
            <given-names>BP</given-names>
          </name>
          <name>
            <surname>Shmookier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sobin</surname>
            <given-names>LH</given-names>
          </name>
          <name>
            <surname>Weiss</surname>
            <given-names>SW</given-names>
          </name>
          <article-title>Diagnosis of gastrointestinal stromal tumors: a consensus approach</article-title>
          <source>Hum Pathol</source>
          <year>2002</year>
          <volume>33</volume>
          <fpage>459</fpage>
          <lpage>465</lpage>
          <pub-id pub-id-type="doi">10.1053/hupa.2002.123545</pub-id>
          <pub-id pub-id-type="pmid">12094370</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rossi</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Mocellin</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mencarelli</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Foletto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pilati</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nitti</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lise</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Gastrointestinal stromal tumors: from a surgical to a molecular approach</article-title>
          <source>Int J Cancer</source>
          <year>2003</year>
          <volume>107</volume>
          <fpage>171</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.11374</pub-id>
          <pub-id pub-id-type="pmid">12949790</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ng</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Pollock</surname>
            <given-names>RE</given-names>
          </name>
          <name>
            <surname>Munsell</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Atkinson</surname>
            <given-names>EN</given-names>
          </name>
          <name>
            <surname>Romsdahl</surname>
            <given-names>MM</given-names>
          </name>
          <article-title>Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging</article-title>
          <source>Ann Surg</source>
          <year>1992</year>
          <volume>215</volume>
          <fpage>68</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1097/00000658-199201000-00010</pub-id>
          <pub-id pub-id-type="pmid">1731651</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rutkowski</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nowecki</surname>
            <given-names>ZI</given-names>
          </name>
          <name>
            <surname>Michej</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Debiec-Rychter</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wozniak</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Limon</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Siedlecki</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grzesiakowska</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Kakol</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Osuch</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Polkowski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gluszek</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zurawski</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Ruka</surname>
            <given-names>W</given-names>
          </name>
          <article-title>Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor</article-title>
          <source>Ann Surg Oncol</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>2018</fpage>
          <lpage>2027</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-007-9377-9</pub-id>
          <pub-id pub-id-type="pmid">17473953</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Xia</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>XT</given-names>
          </name>
          <article-title>Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors</article-title>
          <source>Surg Today</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>936</fpage>
          <lpage>942</lpage>
          <pub-id pub-id-type="doi">10.1007/s00595-009-4171-x</pub-id>
          <pub-id pub-id-type="pmid">20872196</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gold</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Dematteo</surname>
            <given-names>RP</given-names>
          </name>
          <article-title>Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance</article-title>
          <source>Ann Surg Oncol</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>1247</fpage>
          <lpage>1248</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-006-9291-6</pub-id>
          <pub-id pub-id-type="pmid">17265116</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pauwels</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Debiec-Rychter</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Stul</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>De Wever</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Van Oosterom</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Sciot</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall</article-title>
          <source>Histopathology</source>
          <year>2005</year>
          <volume>47</volume>
          <fpage>41</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.2005.02179.x</pub-id>
          <pub-id pub-id-type="pmid">15982322</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Akiyoshi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Oya</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fujimoto</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kuroyanagi</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ueno</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yamaguchi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hatake</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Katori</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yamamoto</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Muto</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case</article-title>
          <source>Surg Today</source>
          <year>2010</year>
          <volume>40</volume>
          <fpage>272</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1007/s00595-008-4037-7</pub-id>
          <pub-id pub-id-type="pmid">20180084</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
